Gynecol Oncol. 2012 Dec;127(3):552-5. doi: 10.1016/j.ygyno.2012.09.009. Epub 2012 Sep 14.
RAD51D, a gene in the Fanconi Anemia-BRCA homologous recombination pathway, has recently been shown to harbor germline mutations responsible for ovarian carcinoma in multiply affected families. We aimed to extend these results to ovarian carcinoma in the general population.
We sequenced RAD51D in germline DNA from 360 individuals with primary ovarian, peritoneal or fallopian tube carcinoma who were not selected for age of cancer onset or family history. We also sequenced RAD51D in 459 probands from 226 high risk breast cancer families who were wild type for 21 breast and ovarian cancer genes.
Of 360 cases, three (0.8%) carried loss-of-function mutations in RAD51D. All three subjects had ovarian carcinoma; one was also diagnosed with a synchronous endometrial carcinoma. Only one of the three subjects had a family history of breast or ovarian cancer. Combined with previous data for this series, 23.9% of women with unselected ovarian, fallopian tube, or peritoneal carcinoma carried a germline loss-of-function mutation in any of 13 tumor suppressor genes. Among the 449 women and 10 men with familial breast cancer, none carried a loss of function mutation in RAD51D.
These data support the previous observation that loss-of-function mutations in RAD51D predispose to ovarian carcinoma but not to breast carcinoma. We conclude that inherited ovarian cancer is highly heterogeneous genetically, and that approximately one in four ovarian carcinoma patients carry a germline mutation in a known tumor suppressor gene that confers high risk.
RAD51D 是范可尼贫血-BRCA 同源重组途径中的一个基因,最近的研究表明,该基因的种系突变可导致多发病例家族的卵巢癌。我们旨在将这些结果扩展到普通人群中的卵巢癌。
我们对 360 名原发性卵巢癌、腹膜癌或输卵管癌患者的种系 DNA 进行 RAD51D 测序,这些患者未根据癌症发病年龄或家族史进行选择。我们还对来自 226 个高风险乳腺癌家族的 459 个先证者进行 RAD51D 测序,这些家族的 21 个乳腺癌和卵巢癌基因均为野生型。
在 360 例病例中,有 3 例(0.8%)携带 RAD51D 功能丧失突变。这 3 名患者均患有卵巢癌,其中 1 名还被诊断为同时性子宫内膜癌。这 3 名患者中只有 1 名有乳腺癌或卵巢癌家族史。将这一系列之前的数据结合起来,在未经选择的卵巢、输卵管或腹膜癌患者中,有 23.9%的患者携带 13 个肿瘤抑制基因中的任何一个种系功能丧失突变。在 449 名女性和 10 名男性的家族性乳腺癌患者中,没有人携带 RAD51D 的功能丧失突变。
这些数据支持之前的观察结果,即 RAD51D 的功能丧失突变易患卵巢癌而不易患乳腺癌。我们得出结论,遗传性卵巢癌在遗传上具有高度异质性,约四分之一的卵巢癌患者携带已知肿瘤抑制基因的种系突变,从而导致高风险。